Newly Diagnosed With Leukemia: First Steps

"Leukemia" is not one illness. The four main adult types differ in how fast they move, what confirms them, and how soon treatment starts.

These are the American Cancer Society's projections for the United States in 2026, as published by NCI's SEER Stat Facts.

• Chronic lymphocytic leukemia: about 22,760 new cases and 4,350 deaths.
• Acute myeloid leukemia: about 22,720 new cases and 11,500 deaths.
• Chronic myeloid leukemia: about 9,650 new cases and 1,170 deaths.
• Acute lymphoblastic leukemia: about 6,250 new cases and 1,600 deaths.

The first question to ask is which one you have. Everything else follows from that answer, including whether you are being admitted this week or sent home to be watched.

AML is diagnosed when blasts, meaning immature blood cells, make up 20% or more of cells in blood or marrow. PDQ notes exceptions. Certain chromosome changes settle the diagnosis at lower blast counts. Those include t(15;17), t(8;21), inv(16), and t(16;16).

The median age at diagnosis is 69. PDQ reports that 31.9% of patients were alive 5 years after diagnosis in data from 2014 to 2020. SEER's own stat facts page has since moved to people diagnosed between 2016 and 2022, and puts the figure a little higher, at 33.4%. About 60% to 70% of adults reach complete remission after appropriate induction treatment, and more than 25% may survive 3 years or longer.

PDQ lists factors that worsen the outlook. Older age is one, and disease in the brain or spinal cord is another. A white blood cell count above 100,000 per cubic millimeter counts. So does an active body-wide infection. The last two are leukemia that followed earlier cancer treatment, and a history of myelodysplastic syndrome or another blood disorder before the leukemia.

If your white blood cell count is very high, do not wait on new shortness of breath, confusion, or changes in vision. Call 911 or go to the nearest emergency department.

Acute promyelocytic leukemia, or APL, makes up 5% to 8% of AML. PDQ notes it is commonly linked to disseminated intravascular coagulation, a bleeding and clotting disorder.

It is also the AML subtype with the best outcomes, because it responds to a specific drug. All-trans retinoic acid, or ATRA, is a differentiating agent. It pushes the abnormal cells to mature. PDQ describes ATRA combined with chemotherapy. It also describes chemotherapy-free regimens built on arsenic trioxide. Both reach high complete remission rates.

This is why the cytogenetic result is urgent, not routine. Ask specifically whether APL has been ruled in or out, and how soon that result is expected.

Call your care team right away for new bleeding from the gums or nose, unusual bruising, or blood in urine or stool. Call 911 or go to the nearest emergency department for bleeding that will not stop, black or tarry stool, blood in vomit or vomit that looks like coffee grounds, or sudden confusion or being hard to wake.

Adult ALL treatment runs in three phases and takes 1.5 to 3 years in total.

Remission induction combines several drugs. The core is vincristine, prednisone, and an anthracycline, with or without asparaginase. PDQ reports complete remission in 60% to 80%.

Central nervous system prophylaxis is a separate phase. It means treatment to prevent leukemia from spreading to the brain and spinal cord. PDQ says it uses chemotherapy given into the spinal fluid, high-dose chemotherapy by vein, and in some cases radiation to the head.

Consolidation follows, using intensive chemotherapy or an allogeneic bone marrow transplant in eligible patients.

One genetic result reshapes the plan. The Philadelphia chromosome appears in roughly 20% of adults with ALL. PDQ notes it may be detectable only by FISH or RT-PCR, so it can be missed on routine chromosome analysis. PDQ says remission rates are generally above 90% when a BCR::ABL1 tyrosine kinase inhibitor is added to standard chemotherapy. In the largest study reported, 1,913 adults with Ph-positive ALL had a 5-year overall survival of 39%.

CML is defined by a single genetic event. PDQ states that over 95% of patients carry the Philadelphia chromosome. It forms when chromosomes 9 and 22 swap material. The result is the BCR::ABL1 fusion gene. It makes an abnormal tyrosine kinase that drives the disease.

Phase is set by blast percentage. Chronic phase is under 10%. Accelerated phase is 10% to 19%. Blastic phase is 20% or more. Most patients present in chronic phase.

PDQ lists five tyrosine kinase inhibitors used first line: asciminib, nilotinib, dasatinib, bosutinib, and imatinib. With any of them, 10-year event-free and overall survival exceed 90%, and PDQ states median survival is projected to approach normal life expectancy.

Monitoring uses the BCR::ABL1 transcript level, measured by RT-PCR:

• Early molecular response: 10% or less at 3 months.
• Major molecular response: 0.1% or less.
• Deep molecular response: 0.01% or less.

PDQ notes that reaching 10% or less at 3 months predicts better long-term outcomes.

Stopping is sometimes discussed, but PDQ is cautious. It says it is unclear whether TKI therapy can be discontinued. The best candidates are people who have taken a TKI for more than 3 to 5 years and reached a deep response of 0.0032% or less. Even then, about 50% relapse after stopping, though one retrospective analysis of people in deep response for 5 years or more put the relapse rate near 10%. Almost all who relapse on PCR testing can be restarted successfully. This is a conversation to have with your hematologist, not a step to take alone.

CLL needs two things. One is a blood lymphocyte count of 5,000 per cubic millimeter or higher. The other is a telltale flow cytometry pattern: B cells carrying CD19 and CD20 alongside CD5, a T-cell marker, plus CD23. PDQ notes only one other disease shows that combination, mantle cell lymphoma.

Then, often, nothing happens. Observation is standard for people without symptoms. PDQ cites a meta-analysis of randomized trials. It found no survival gain from early treatment over delayed treatment in early-stage disease. Treatment begins for progressive marrow failure or symptomatic disease.

That waiting is a plan, not neglect. It helps to have the prognostic numbers PDQ gives. They come from single studies, so treat them as rough.

• del(17p): the most unfavorable group, median overall survival about 7 years in one prospective trial.
• del(13q): favorable, median overall survival about 17 years in one prospective study.

Frontline options PDQ names include ibrutinib, acalabrutinib, and venetoclax. Chemotherapy with fludarabine, cyclophosphamide, and rituximab is still an option. It suits younger patients with mutated IGHV best.

Rai staging runs from stage 0, lymphocytosis alone, to stage IV, lymphocytosis with low platelets. The Binet system sorts patients into A, B, or C.

If you are on chemotherapy, have had a stem cell transplant, or have low white blood cell counts, infection can be dangerous. Call your care team right away, day or night, for a fever of 100.4 degrees F (38 degrees C) or higher. Also call right away for chills, a sore throat, mouth sores, burning when you urinate, or redness at a catheter site. Do this even if your temperature is normal. Do not wait until morning.

Across types, the workup is similar in shape. Your team may add other blood tests.

• Complete blood count with differential.
• Bone marrow aspirate and biopsy. For CLL, PDQ says this is usually not required.
• Flow cytometry, which identifies the cell type by its surface markers.
• Cytogenetic analysis. PDQ calls it mandatory in suspected AML. About 50% of those cases carry a chromosome abnormality.
• Molecular testing. In AML, PDQ names NPM1, FLT3, CEBPA, and RUNX1. In ALL and CML, RT-PCR and FISH for BCR::ABL1.

In AML, PDQ ranks cytogenetic and molecular results as the strongest guide to outlook. They predict how induction and consolidation therapy will go.

• Exactly which leukemia is this, and what confirmed it?
• What was my blast percentage, and in blood or in marrow?
• Have cytogenetics and molecular testing been sent, and when do results return?
• For AML, has APL been ruled out?
• Does my plan start now, or is observation appropriate?
• What is my white blood cell count, and does it need lowering urgently?
• Which symptoms should send me to the emergency department rather than the clinic?
• Who do I call day or night if I have a fever, chills, or any sign of infection?

• https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq
• https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq
• https://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq
• https://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq